What the clinical research actually shows Three categories of evidence exist regarding semaglutide and blood clots: randomized controlled trials, real-world observational studies, and individual case reports
It was already described in this charter
That might mean restoring sleep rhythm, introducing resistance training to rebuild muscle mass, restructuring meal timing, or helping someone regulate stress so their nervous system is not constantly in a threat state
As a potent dual receptor agonist, this compound is extensively studied for its synergistic interaction with both the GLP-1 (Glucagon-like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide) receptor pathways
--- Sources Neeland et al., Changes in lean body mass with GLP-1-based therapies and mitigation strategies , Diabetes, Obesity and Metabolism (2024): Jensterle et al., Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass , DOM (2026): Wilding et al., STEP 1 body composition exploratory analysis: LEAN-PREP randomised controlled trial protocol (2025): Function and Lean Mass Preservation With Resistance Exercise During GLP-1RA Treatment, ClinicalTrials.gov: WHO Guidelines on Physical Activity and Sedentary Behaviour: Wegovy Singapore availability and prescription status:
Real-world data suggests comparable weight loss outcomes between oral and injectable semaglutide when doses are optimized, though individual results vary more with oral formulations
